Huang Xiaoxu, Li Yin, Zhuang Pan, Liu Xiaohui, Zhang Yu, Zhang Pianhong, Jiao Jingjing
Department of Clinical Nutrition, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Nutrition, School of Public Health, Department of Clinical Nutrition, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Nutr. 2022 Jul 12;9:905162. doi: 10.3389/fnut.2022.905162. eCollection 2022.
Inflammatory Bowel Diseases (IBDs) have been emerging in recent years with the advance of global industrialization and diet pattern transformation. Marine n-3 polyunsaturated fatty acids (n-3 PUFAs), enriched in fish oils, have well-known human health promotion. Evidence on the association of fish oil supplementation with the risk of developing IBDs was scarce. This study aimed to examine the association between the use of fish oil supplements and the risk of developing inflammatory bowel diseases (IBDs) among the general population.
We conducted a prospective cohort study of 447,890 participants aged 40-69 years from the UK Biobank. A touch screen questionnaire was used to get the data about fish oil intake at baseline. Incident diagnoses of IBDs were ascertained by the International Classification of Diseases (ICD-9 and ICD-10) or self-report. Cox proportional hazards model was applied to calculate hazard ratios () and 95% confidence intervals () of developing IBDs and their subtypes.
We documented 1,646 incident cases of IBDs, including 533 incident cases of Crohn's disease (CD) and 1,185 incident cases of ulcerative colitis (UC) during an average of 8 years of follow-up. After multivariate adjustment, the use of fish oil was associated with a 12% lower risk of IBDs (: 0.88, 95% : 0.78-0.99, = 0.03) compared with non-consumers. For subtypes of IBDs, fish oil supplementation was inversely associated with a 15% lower risk of UC (: 0.85, 95% : 0.75-0.99, = 0.02) but was not correlated with the risk of CD ( = 0.22). Besides, fish oil supplementation showed a significant inverse correlation with baseline CRP levels (β = -0.021, < 0.001) and a positive association with baseline albumin levels (β = 0.135, < 0.001) after adjustment for multiple variates.
Habitual intake of fish oil supplements was associated with a lower risk of IBDs and UC. Fish oil users tended to have lower baseline C-reactive protein levels and higher baseline albumin levels compared with non-users. It was concluded that fish oil supplement use may be recommended for the prevention and control of IBDs.
近年来,随着全球工业化进程的推进和饮食模式的转变,炎症性肠病(IBD)的发病率不断上升。富含鱼油的海洋n-3多不饱和脂肪酸(n-3 PUFAs)对人类健康具有显著的促进作用。然而,关于补充鱼油与IBD发病风险之间关系的证据却十分匮乏。本研究旨在探讨在普通人群中,服用鱼油补充剂与患炎症性肠病(IBD)风险之间的关联。
我们对英国生物银行中447,890名年龄在40 - 69岁之间的参与者进行了一项前瞻性队列研究。通过触摸屏问卷收集基线时的鱼油摄入量数据。IBD的确诊依据国际疾病分类(ICD - 9和ICD - 10)或自我报告。采用Cox比例风险模型计算患IBD及其亚型的风险比(HR)和95%置信区间(CI)。
在平均8年的随访期间,我们共记录了1,646例IBD新发病例,其中包括533例克罗恩病(CD)和1,185例溃疡性结肠炎(UC)。多因素调整后,与未服用者相比,服用鱼油与IBD发病风险降低12%相关(HR:0.88,95%CI:0.78 - 0.99,P = 0.03)。对于IBD的亚型,补充鱼油与UC发病风险降低15%呈负相关(HR:0.85,95%CI:0.75 - 0.99,P = 0.02),但与CD发病风险无关(P = 0.22)。此外,在对多个变量进行调整后,补充鱼油与基线CRP水平呈显著负相关(β = - 0.021,P < 0.001),与基线白蛋白水平呈正相关(β = 0.135,P < 0.001)。
习惯性服用鱼油补充剂与IBD和UC的发病风险降低相关。与未使用者相比,服用鱼油者的基线C反应蛋白水平较低,基线白蛋白水平较高。因此,建议使用鱼油补充剂来预防和控制IBD。